Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing
VR Placencio, YA DeClerck - Cancer research, 2015 - AACR
VR Placencio, YA DeClerck
Cancer research, 2015•AACRDespite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA),
PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting
angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in
support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule
PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer.
The review discusses the challenges and the opportunities that lay ahead to the …
PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting
angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in
support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule
PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer.
The review discusses the challenges and the opportunities that lay ahead to the …
Abstract
Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents. Cancer Res; 75(15); 2969–74. ©2015 AACR.
AACR